Finally,I get you! 13 pharmaceutical companies to be listed in Hong Kong in the second half of the year

Source: Sina Pharmaceutical News May 25, 2018, following the opening of the green channel of the Hong Kong stock exchange, more and more high-quality medical and health enterprises and biotechnology companies will land on the Hong Kong stock exchange Li Xiaojia, chief executive of the Hong Kong stock exchange, expected that "the number will certainly not be a single digit, and more than 10 enterprises are likely to apply." It is expected that the first such shares will be listed on the Hong Kong Stock Exchange as soon as June to July " Li Xiaojia: the second half of the year will usher in the peak of listing on May 17 Li Xiaojia, chief executive of the Hong Kong stock exchange, said at the LME Asia annual meeting in Hong Kong that it was inconvenient to disclose how many companies applied for listing in Hong Kong under the same share structure with different rights for the time being Considering that the new rules were only adopted at the end of April, it is expected that after August, there will be a peak of listing "Every year, the peak of listing is in the second half of the year There are audit factors and holiday factors The new regulations come into effect at the end of April It is expected that more companies will be listed after August September to November are the peak of listing." Li Xiaojia said that more and more biotech companies with different rights and unprofitable shares apply for listing in Hong Kong, because many companies have been in close communication with the listing section of the Hong Kong stock exchange On February 23, 2018, the Hong Kong Stock Exchange issued the consultation document on the listing system of Companies in emerging and innovative industries (hereinafter referred to as the consultation document) According to the consultation document, the Hong Kong Stock Exchange will allow the following companies to be listed in Hong Kong: biotechnology companies that fail to pass the financial qualification test, including companies that have no earnings or profit records; High growth and innovative industrial companies with different voting power structures; looking for secondary listed and qualified Issuers on the stock exchange So far, HKEx has ushered in the most important listing system reform in 25 years With the opening of the green channel, HKEx has gradually become the first choice for mainland growth enterprises to enter the capital market Photo source: Companies in mainland China, especially innovative pharmaceutical and biological companies, are enthusiastic about going public in Hong Kong On May 4, 2018, Ping An Hao doctor, known as unicorn, was officially listed and traded on the main board of the Hong Kong stock exchange, which also means the first share of global AI medical technology was officially born On May 8, another unicorn, yaomingkant, was officially listed on A-share, with an issue price of 21.6 yuan Up to the time of publication, there have been 13 trading boards up to 97.60 yuan In addition, there are medical and health companies such as Weiyi, Fuhong Hanlin and so on, all of which have reported going public in Hong Kong So, which pharmaceutical companies will take the lead in going public in Hong Kong? Combined with the public information, Sina pharmaceutical has listed 13 pharmaceutical companies that may go to Hong Kong for listing in the second half of 2018 List of potential listed companies in Hong Kong in the second half of 2018 1 Profile of Xinda Bio: Xinda bio was established in Suzhou in 2011 with a registered capital of RMB 525 million Product line: with 13 new antibody product lines, the treatment field covers four major disease fields, including tumor, autoimmune disease, fundus disease, cardiovascular disease, etc Among them, five products have been selected into the national "major new drug creation" major science and technology projects, and four products have entered the clinical phase III Financing situation: in October 2011, the company obtained 5 million USD round a investment, which was invested by stork capital (formerly fidelity Asia) and f-prime Capital Partners In June 2012, it obtained 30 million US dollars in round B investment, and invested by Lilly Asia Fund, stork capital (fidelity Asia) and f-prime Capital Partners In January 2015, the company obtained US $115 million round C investment, which was jointly funded by new investors such as Junlian capital, Singapore Temasek and Hillhouse capital under Lenovo holding and original investors such as fidelity, Lilly Asia Fund, Tonghe capital In November 2016, a total of 262 million US dollars of D rounds of financing was completed, which was led by SDIC innovation, followed by Guoshou health fund, Junlian capital, Licheng asset, Ping An, Taikang Insurance Group, etc News source: on January 16, 2018, endpoints, a well-known foreign medical information website, quoted Bloomberg as saying that Cinda biology is carrying out a $150 million pre IPO round financing, with a post investment valuation of more than $1 billion, but the IPO market has not yet been determined At the end of 2017, Yu Dechao, the founder of the company, said that he would make a choice between NASDAQ and HKEx Recent developments: on April 27, Cinda biology announced the completion of 150 million US dollars e-round financing This time, four new investment institutions, capital group private markets (CGPM) led the investment of 90 million US dollars, and cormorant asset management, Rock Springs Capital and Huiqiao capital follow the investment, and other investors include old shareholders Temasek, Hillhouse capital, Junlian capital, Lilly Asia Fund and Taikang Insurance This round of investment is valued at more than $1 billion 2 Fuhong Hanlin Company Profile: Fuhong Hanlin was jointly established by Fosun Pharmaceutical and the US scientists team in December 2009, with a registered capital of 450 million yuan (as of January 10, 2018) Product line: as of April 2018, Fuhong Hanlin has completed the declaration of 11 products and 16 IND indications, covering tumor, autoimmune diseases and other fields Fuhong Hanlin has completed the first five items of clinical registration application hlx01-hlx05, all of which are biologically similar drugs of "heavyweight monoclonal antibody" in the world Fuhong Hanlin product line picture source: Fuhong Hanlin official website financing: on March 1, 2016, obtained 4 million US dollars Angel round financing, the investor is founder and life investment On April 12, 2016, Liu Shigao, the founder of the company, Jiang Weidong, the chief scientific officer, and the employee shareholding platform increased the capital of the company by 6.696 million yuan On May 27, 2016, it completed external financing of US $40 million, led by Huagai capital, followed by Qingke venture capital, Yuansheng venture capital, Orient Securities (Dongfang Xinghui), founder Hesheng investment, with a post investment valuation of about US $490 million In January 2018, gotega, Jacobson Pharma Corp and others completed investment of about $190 million, making Fuhong Hanlin valued at more than $1.5 billion (about 10 billion people) Source: in February 2018, Bloomberg quoted people familiar with the matter as saying that Fuhong Hanlin Biotechnology Co., Ltd., a subsidiary of Fosun Pharmaceutical, is likely to issue shares in Hong Kong in the second half of this year, raising at least $500 million Recent developments: the company is expected to land in Hong Kong stock market in the second half of 2018, and has entered the period of silence before listing 3 Profile of Shanghai Tianshili pharmaceutical company: founded in 2001, it is a wholly-owned subsidiary of Tianshili Pharmaceutical Group Co., Ltd at present, it has invested about 400 million yuan in the construction of gene engineering, large-scale cell culture, protein purification and freeze-dried powder injection production line and modern office facilities in accordance with the requirements of GMP 2010 Product line: the company's research and development of biological products for injection of recombinant human urokinase (trade name puyouke) has been successfully marketed in 2012 for thrombolytic therapy of acute ST segment elevation acute myocardial infarction According to Tianshili announcement, the sales volume of puyouke in 2016 was 38 million yuan In June 2017, the product entered the new national medical insurance catalog through negotiation, and the sales revenue is expected to exceed 100 million yuan in 2017 According to research reports released by several securities companies, the market space of puyouke is about 3 billion yuan Shanghai Tianshili has several heavy-duty products in the R & D stage, with market space of more than 1 billion News source: at the beginning of March 2018, Reuters reported that Shanghai Tianshili, a subsidiary of Tianshili, is expected to complete IPO in the second half of 2018, with a financing scale of about US $1 billion If the listing is successful, Shanghai Tianshili will become the Unicorn with the highest valuation among the bio pharmaceutical enterprises applying for Hong Kong stock listing Recent developments: in the evening of March 26, tisley disclosed its annual report that, according to the company's business plan for 2018, it decided to take Shanghai tisley as the main body, split the bio pharmaceutical sector from its parent company and list it in the Hong Kong H-share main board market The company is working with the proposed share sale consultant, but details such as the valuation, the type of shares to be sold and the exact percentage of shares to be listed have not been officially announced 4 Hualing Pharmaceutical Company Profile: founded in 2011 with registered capital of USD 21.067 million, the company focuses on the development of diabetes products Product line: the current research and development fields include type 2 diabetes drugs and central nervous system disorders drugs Dorzagliatin, a candidate drug in Hualing R & D pipeline, helps patients with type 2 diabetes by regulating carbohydrate metabolism This is the first new drug in the world Two phase III clinical studies have been conducted in China Picture source of R & D pipeline of Hualing pharmaceutical: financing of Hualing pharmaceutical official website: at the end of 2013, it obtained a round of investment of US $10 million, with arch, venlock, Fidelity's Sidao capital, Wuxi ventures, Shanghai Lianhe jointly participating in the investment In January 2015, it obtained 25 million USD round B investment, led by Huiqiao capital group Three new institutional investors participated by Tonghe capital and Taifu capital, as well as five original round a investors, arch, venlock, fidelity, Wuxi ventures and Shanghai Lianhe, participated in the completion In April 2016, we completed the US $50 million round C financing in both US dollar and RMB currencies, including harvest investment leading investment, Tonghe capital following investment, and Huaxing capital acting as the exclusive financial consultant Source: according to Bloomberg and Reuters, Hualing pharmaceutical plans to IPO in Hong Kong in the second half of 2018, raising 300 million or 400 million US dollars Hualing pharmaceutical had considered listing in New York or Hong Kong, but finally chose Hong Kong as the listing place, because the Hong Kong exchange and Clearing Company Limited is expected to implement a new listing system within a few months Recent developments: on March 27, 2018, Hualing pharmaceutical announced the completion of round D and round e financing, raising a total of US $117.4 million (about HK $920 million), including Alibaba Chairman Ma Yun and executive vice chairman Cai Chongxin's private investment fund blue pool capital, GIC private held by Singapore sovereign fund, Ping An Innovation Investment Fund, etc It is reported that all the funds raised are expected to be used to support the company to complete two phase III clinical trials of the world's first diabetes mellitus dorzagliatin (hms5552) in China, as well as the preparation before commercialization Hms5552 is a global first in class new drug for type II diabetes 5 Yongtai biological enterprise profile: founded in 2006, with a registered capital of 22.7546 million yuan Committed to the application of advanced immunology, cell biology, genetics and other theories, combined with the international advanced adoptive immunotherapy, research and development of immunotherapy and clinical application of major diseases such as tumor Product line: the expanded activated lymphocyte (EAL), a cell treatment product with proprietary technology of Yongtai biology, applied for ind to CDE as early as 2015, and obtained the "drug clinical trial approval" issued by the General Administration on October 17, 2017 It is reported that the clinical approval document is the first cell immunotherapy product in China to apply for clinical application and obtain approval according to the drug regulatory path In addition to the project of expanding activated lymphocytes, Yongtai biological's product line under development also includes the ovarian cancer specific T cell product "6B11 specific ovarian cancer CIK injection" based on the micro antibody technology, which has obtained the phase I clinical approval, and intends to declare the car-t CD19 cell therapy of ind At present, Yongtai biology has formed a complete cell drug system including non-specific immune cell preparations, specific immune cell preparations and gene modified immune cell preparations, creating an anti-tumor and anti-virus infection system